Measles Is Becoming So Common That Treatments May Soon Be Needed
Measles cases in the US have reached a 35-year high, prompting biotech firms to explore new monoclonal antibody treatments for infected individuals. While vaccines remain the primary defense, researchers are seeking options for those who are immunocompromised or unvaccinated.
But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection. It will likely be years, however, before these countermeasures are available, and it’s even more uncertain if those who refuse vaccines would take such treatments.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in